Lincoln Pharma Eyes ₹1000 Crore Revenue Mark in Next Three Years.

Lincoln Pharmaceuticals, the Ahmedabad-based formulations manufacturer, is targeting a significant revenue milestone, aiming to reach ₹1,000 crore within the next three years. This ambitious goal represents a nearly 55 percent growth for the company.

Munjal Patel, whole-time director at Lincoln Pharmaceuticals, shared this outlook during an earnings call following the company's fourth-quarter results for the fiscal year 2024-25. "We will grow by 15-18 percent yearly. So we are looking at roughly around ₹1,000 crores (in revenues) within the next three years," Patel stated.

The company anticipates that its future growth will be primarily driven by key therapeutic segments including cardiac, diabetic, derma, and ENT. For the recently concluded FY25, Lincoln Pharmaceuticals reported a 5 percent year-on-year increase in revenues, reaching ₹647 crore. Domestic market contributions saw maximum input from states such as Uttar Pradesh, Assam, and Odisha.